vs
爱玛客（ARMK）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
爱玛客的季度营收约是梯瓦制药的1.0倍（$4.8B vs $4.7B），梯瓦制药净利率更高（10.2% vs 2.0%，领先8.2%），梯瓦制药同比增速更快（11.4% vs 6.1%），梯瓦制药自由现金流更多（$1.0B vs $-904.4M），过去两年梯瓦制药的营收复合增速更高（11.1% vs 7.3%）
爱玛客是美国知名的餐饮服务与设施管理服务商，服务覆盖教育、司法监管、医疗、企业、休闲文旅等多个领域，业务遍布北美地区及英国、德国、智利、爱尔兰、西班牙在内的14个国家，为各场景客户提供专业后勤支持解决方案。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
ARMK vs TEVA — 直观对比
营收规模更大
ARMK
是对方的1.0倍
$4.7B
营收增速更快
TEVA
高出5.3%
6.1%
净利率更高
TEVA
高出8.2%
2.0%
自由现金流更多
TEVA
多$1.9B
$-904.4M
两年增速更快
TEVA
近两年复合增速
7.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8B | $4.7B |
| 净利润 | $96.2M | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | 4.5% | 6.4% |
| 净利率 | 2.0% | 10.2% |
| 营收同比 | 6.1% | 11.4% |
| 净利润同比 | -9.0% | 321.7% |
| 每股收益（稀释后） | $0.36 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARMKTEVA
| Q1 26 | $4.8B | — | ||
| Q4 25 | $5.0B | $4.7B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | $4.6B | $4.2B | ||
| Q1 25 | $4.3B | $3.9B | ||
| Q4 24 | $4.6B | $4.2B | ||
| Q3 24 | $4.4B | $4.3B | ||
| Q2 24 | $4.4B | $4.2B |
净利润ARMKTEVA
| Q1 26 | $96.2M | — | ||
| Q4 25 | $87.1M | $481.0M | ||
| Q3 25 | — | $433.0M | ||
| Q2 25 | $71.8M | $282.0M | ||
| Q1 25 | $61.9M | $214.0M | ||
| Q4 24 | $105.6M | $-217.0M | ||
| Q3 24 | $122.4M | $-437.0M | ||
| Q2 24 | $58.1M | $-846.0M |
毛利率ARMKTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% |
营业利润率ARMKTEVA
| Q1 26 | 4.5% | — | ||
| Q4 25 | 4.3% | 6.4% | ||
| Q3 25 | — | 19.7% | ||
| Q2 25 | 3.9% | 10.9% | ||
| Q1 25 | 4.1% | 13.3% | ||
| Q4 24 | 4.8% | -0.7% | ||
| Q3 24 | 5.0% | -1.2% | ||
| Q2 24 | 3.7% | -0.1% |
净利率ARMKTEVA
| Q1 26 | 2.0% | — | ||
| Q4 25 | 1.7% | 10.2% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | 1.6% | 6.8% | ||
| Q1 25 | 1.4% | 5.5% | ||
| Q4 24 | 2.3% | -5.1% | ||
| Q3 24 | 2.8% | -10.1% | ||
| Q2 24 | 1.3% | -20.3% |
每股收益（稀释后）ARMKTEVA
| Q1 26 | $0.36 | — | ||
| Q4 25 | $0.33 | $0.42 | ||
| Q3 25 | — | $0.37 | ||
| Q2 25 | $0.27 | $0.24 | ||
| Q1 25 | $0.23 | $0.18 | ||
| Q4 24 | $0.39 | $-0.19 | ||
| Q3 24 | $0.46 | $-0.39 | ||
| Q2 24 | $0.22 | $-0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $439.6M | $3.6B |
| 总债务越低越好 | $6.2B | — |
| 股东权益账面价值 | $3.2B | $7.9B |
| 总资产 | $13.5B | $40.7B |
| 负债/权益比越低杠杆越低 | 1.94× | — |
8季度趋势，按日历期对齐
现金及短期投资ARMKTEVA
| Q1 26 | $439.6M | — | ||
| Q4 25 | $639.1M | $3.6B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $501.5M | $2.2B | ||
| Q1 25 | $920.5M | $1.7B | ||
| Q4 24 | $484.1M | $3.3B | ||
| Q3 24 | $672.5M | $3.3B | ||
| Q2 24 | $436.1M | $2.3B |
总债务ARMKTEVA
| Q1 26 | $6.2B | — | ||
| Q4 25 | $5.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $5.0B | — |
股东权益ARMKTEVA
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.1B | $7.9B | ||
| Q3 25 | — | $7.3B | ||
| Q2 25 | $3.1B | $6.8B | ||
| Q1 25 | $3.0B | $6.3B | ||
| Q4 24 | $3.1B | $5.4B | ||
| Q3 24 | $3.0B | $6.1B | ||
| Q2 24 | $2.9B | $6.4B |
总资产ARMKTEVA
| Q1 26 | $13.5B | — | ||
| Q4 25 | $13.3B | $40.7B | ||
| Q3 25 | — | $39.9B | ||
| Q2 25 | $13.3B | $40.1B | ||
| Q1 25 | $13.5B | $38.4B | ||
| Q4 24 | $12.7B | $39.3B | ||
| Q3 24 | $12.7B | $41.8B | ||
| Q2 24 | $12.5B | $41.3B |
负债/权益比ARMKTEVA
| Q1 26 | 1.94× | — | ||
| Q4 25 | 1.71× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.03× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 1.61× | — | ||
| Q3 24 | 1.42× | — | ||
| Q2 24 | 1.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-782.2M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $-904.4M | $1.0B |
| 自由现金流率自由现金流/营收 | -18.7% | 21.6% |
| 资本支出强度资本支出/营收 | 2.5% | 3.0% |
| 现金转化率经营现金流/净利润 | -8.13× | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $1.1B |
8季度趋势，按日历期对齐
经营现金流ARMKTEVA
| Q1 26 | $-782.2M | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $369.0M | ||
| Q2 25 | $76.7M | $227.0M | ||
| Q1 25 | $255.9M | $-105.0M | ||
| Q4 24 | $-587.2M | $575.0M | ||
| Q3 24 | $1.0B | $693.0M | ||
| Q2 24 | $140.7M | $103.0M |
自由现金流ARMKTEVA
| Q1 26 | $-904.4M | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | $-34.7M | $131.0M | ||
| Q1 25 | $140.1M | $-232.0M | ||
| Q4 24 | $-707.0M | $446.0M | ||
| Q3 24 | $882.3M | $545.0M | ||
| Q2 24 | $55.6M | $6.0M |
自由现金流率ARMKTEVA
| Q1 26 | -18.7% | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | -0.8% | 3.1% | ||
| Q1 25 | 3.3% | -6.0% | ||
| Q4 24 | -15.5% | 10.5% | ||
| Q3 24 | 20.0% | 12.6% | ||
| Q2 24 | 1.3% | 0.1% |
资本支出强度ARMKTEVA
| Q1 26 | 2.5% | — | ||
| Q4 25 | 2.8% | 3.0% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | 2.4% | 2.3% | ||
| Q1 25 | 2.7% | 3.3% | ||
| Q4 24 | 2.6% | 3.1% | ||
| Q3 24 | 3.2% | 3.4% | ||
| Q2 24 | 1.9% | 2.3% |
现金转化率ARMKTEVA
| Q1 26 | -8.13× | — | ||
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | 1.07× | 0.80× | ||
| Q1 25 | 4.14× | -0.49× | ||
| Q4 24 | -5.56× | — | ||
| Q3 24 | 8.35× | — | ||
| Q2 24 | 2.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARMK
| Education | $1.1B | 22% |
| Sports Leisure Corrections | $961.2M | 20% |
| Food And Support Services International | $847.8M | 18% |
| Other | $621.6M | 13% |
| Businessand Industry | $510.6M | 11% |
| Health Care | $421.3M | 9% |
| Facility Services | $382.9M | 8% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
